Cytochrome P450 2C19 polymorphism and clopidogrel after MI

被引：4
|
作者：
Bhattacharyya, Sanjeev [1 ]
Rakhit, Roby [1 ]
机构：
[1] Royal Free Hosp, Dept Cardiol, London NW3 2QG, England
来源：
LANCET | 2009年 / 373卷 / 9670期
关键词：
OUTCOMES;
D O I：
10.1016/S0140-6736(09)60679-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1171 / 1171
页数：1
相关论文
共 50 条
  • [31] Efficacy and Adverse Events of Clopidogrel and Ticagrelor in Patients with Cytochrome P450 2C19 Gene Deletion
    Cai, Xiaofang
    Jiang, S. J.
    Chen, Jiana
    Cai, Xiujuan
    Wang, W. L.
    Huang, J. D.
    Zhang, J. H.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 175 - 181
  • [32] THE SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN CYTOCHROME P450 2C19 AND CLOPIDOGREL RESISTANCE IN INDIAN POPULATION
    Shivaraman, M. M. Arun
    Nazarene, Anto
    Ranganathan, Lakshmi Narasimhan
    Chandar, Christianne Sandhya Ravi
    Kumar, S. Pratheep
    Shankar, Gobinathan
    NEUROLOGY, 2017, 88
  • [33] Cytochrome P450 2C19 681G > A polymorphism in coronary heart disease patients treated with clopidogrel in Chinese
    Tang, Xiaofang
    Yuan, Jinqing
    Yang, Yuejin
    CARDIOLOGY, 2013, 126 : 144 - 144
  • [34] CYTOCHROME P450 2C19 681G>A POLYMORPHISM IN CORONARY HEART DISEASE PATIENTS TREATED WITH CLOPIDOGREL IN CHINESE
    Tang, Xiaofang
    Yuan, Jinqing
    Yang, Yuejin
    He, Chen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1206 - E1206
  • [35] In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong
    Chen, Hui
    Zhang, Ya
    Wu, Xiaoying
    Li, Candong
    Wang, Huan
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012
  • [36] Is 17 α-ethinyl estradiol an inhibitor of cytochrome P450 2C19?
    Rodrigues, AD
    Lu, P
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (03) : 364 - 365
  • [37] Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19
    R Timm
    R Kaiser
    J Lötsch
    U Heider
    O Sezer
    K Weisz
    M Montemurro
    I Roots
    I Cascorbi
    The Pharmacogenomics Journal, 2005, 5 : 365 - 373
  • [38] Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
    Ikeda, Y
    Umemura, K
    Kondo, K
    Sekiguchi, K
    Nakashima, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) : 587 - 588
  • [39] Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel
    Nishiya, Y.
    Hagihara, K.
    Kurihara, A.
    Okudaira, N.
    Farid, N. A.
    Okazaki, O.
    Ikeda, T.
    XENOBIOTICA, 2009, 39 (11) : 836 - 843
  • [40] Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel
    Nishio, Ryo
    Shinke, Toshiro
    Otake, Hiromasa
    Sawada, Takahiro
    Haraguchi, Yoko
    Shinohara, Masakazu
    Toh, Ryuji
    Ishida, Tatsuro
    Nakagawa, Masayuki
    Nagoshi, Ryoji
    Kozuki, Amane
    Inoue, Takumi
    Hariki, Hirotoshi
    Osue, Tsuyoshi
    Taniguchi, Yu
    Iwasaki, Masamichi
    Hiranuma, Noritoshi
    Konishi, Akihide
    Kinutani, Hiroto
    Shite, Junya
    Hirata, Ken-ichi
    CIRCULATION JOURNAL, 2012, 76 (10) : 2348 - 2355
12345